This is a customer win but lacks firm commitments, no minimum purchases and no guidance update. Monitor the November 2026 earnings call for quantification. The stock may see a modest positive reaction on the new CSL relationship, but revenue visibility remains low.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 18 $104.65entry
- T+1 · 3mo ago +3.59%α +3.38% · $108.41
- T+5 · 3mo ago +3.51%α +3.71% · $108.32
- T+20 · 2mo ago +0.98%α +1.97% · $105.68
- T+60 · 6d ago +16.92%α +18.96% · $122.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Haemonetics entered into a non-exclusive supply agreement with CSL Plasma for use of its NexSys PCS devices and disposables in the U.S. No minimum purchase commitments; scope and timing of transition are undetermined. The company is not updating its fiscal 2027 guidance and will provide an update on the expected impact during its second fiscal quarter earnings call in November 2026.
Key Facts
- Non-exclusive supply agreement with CSL Plasma Inc. signed August 14, 2026.
- CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S.
- The agreement contains no minimum purchase commitments.
- Scope and timing of CSL's center transitions have not yet been determined.
- No update to previously issued fiscal 2027 guidance.
- Company expects to provide an impact update in November 2026 on the second fiscal quarter earnings call.
Financial Impact
No dollar amounts disclosed; agreement is non-exclusive and has no minimum purchase commitments, so near-term revenue impact is uncertain.
Risk Factors
- CSL may transition only a small number of centers or delay implementation.
- No minimum purchase commitments create downside risk to expected revenue.
- Competitors could retain or regain share at CSL centers.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313143-26-000135 |
| Document: 0000313143-26-000135-index-headers.html | 0000313143-26-000135 |
| Document: 0000313143-26-000135-index.html | 0000313143-26-000135 |
| Document: 0000313143-26-000135.txt | 0000313143-26-000135 |
Track record
14 reports on HAE
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
- Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
- Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Aug 18, 202612w ago 8-K Neutral 3/10 Viewing Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers